Consistently, the percentage of huCD45 leukemia cells were significantly reduced in bone marrows collected from the fusion protein–treated mice compared with the control A192 groups (FLT3-A192 vs. A192, P < 0.0001, 58% decrease; CD99-A192 vs. A192, P = 0.0003, 41% decrease; Co-Assembled vs. A192, P < 0.0001, 60% decrease; Fig. 5E and F). This evidence concerns the gene FLT3 and leukemia.